GSK1838705A is primarily utilized in the field of cancer research due to its role as an inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) and the anaplastic lymphoma kinase (ALK). It is particularly studied for its potential to inhibit tumor growth in various cancers, including non-small cell lung cancer (NSCLC) and other malignancies where IGF-1R and ALK pathways are implicated. Researchers use GSK1838705A to explore its efficacy in blocking these signaling pathways, which are crucial for cancer cell proliferation and survival. Its application extends to preclinical studies, where it helps in understanding the molecular mechanisms of cancer and in evaluating its potential as a therapeutic agent in targeted cancer therapies.